You are here

R&D

Fast-growing Gilead buys an R&D campus for $135M

Endpoints

Mon, 01/22/18 - 05:39 pm

Gilead Sciences

Big Pharma invests in research for new antibiotics ($2bn)

GoinPharma

Sun, 01/21/18 - 09:05 pm

AstraZeneca gives itself top marks for R&D productivity makeover — but the jury is still out

Endpoints

Fri, 01/19/18 - 11:34 am

Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab

Endpoints

Mon, 01/15/18 - 09:37 am

cancer vaccines

Decoding cancer-linked enzyme could lead to better EGFR cancer drugs

Fierce Pharma

Sun, 01/14/18 - 09:56 am

Concert rethinks R&D plans after loss in Incyte patent case

Fierce Biotech

Fri, 01/12/18 - 06:40 pm

Concert Pharmaceuticals

Shire CEO Flemming Ornskov is hatching a few new stretch goals for R&D in 2018 — and beyond

Endpoints

Fri, 01/12/18 - 10:36 am

Flemming Ornskov

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Endpoints

Thu, 01/11/18 - 09:53 am

Charles River Laboratories

JPM18: Incyte and Syros to collaborate in cancer R&D

Biopharma Dive

Wed, 01/10/18 - 06:57 pm

Syros Pharmaceuticals

GSK’s long-quiet cancer R&D group is ready to make some noise as it mounts a breakout late-stage effort

Endpoints

Wed, 01/10/18 - 10:15 am

Pfizer is axing its neurosciences division, laying off 300 and discarding new drugs

Endpoints

Sun, 01/7/18 - 12:50 pm

Deal-hungry Takeda hands over $150M to Denali for neurodegenerative work

Fierce Biotech

Sat, 01/6/18 - 12:30 pm

neurodegenerative disease

J&J does Alzheimer’s gene therapy deal, along with 14 other new collaborations

Endpoints

Fri, 01/5/18 - 10:31 am

Alzheimer's disease

Holobiome Corporation

Beacon Discovery

Here's Where Things Went Wrong for Celgene Corporation in 2017

Motley Fool

Fri, 12/29/17 - 10:44 am

autoimmune disease

Illinois AG sues Baxter for polluting lake

Drug Delivery Business News

Thu, 12/21/17 - 11:50 am

Baxter International

Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt

Endpoints

Wed, 12/13/17 - 09:23 am

Teva Pharmaceutical

Sanofi’s R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco

Endpoints

Tue, 12/12/17 - 10:12 am

Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma?

Endpoints

Mon, 12/11/17 - 09:55 am

Have PRVs Incentivized New Rare or Neglected Disease Research? Experts Discuss

RAPS.org

Sat, 12/9/17 - 02:27 pm

priority review vouchers

drug development

There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?

Endpoints

Thu, 12/7/17 - 09:24 am

immuno-oncology

drug development

Pages